Carcinoma, Non-Small Cell Lung — Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC
Citation(s)
CONSIST: A Phase III Randomized Control Study of Consolidation Sintilimab (IBI308) After Concurrent Chemoradiation Versus Chemoradiation Alone in Patients With Unresectable Local Advanced Stage III NSCLC